Spinal Muscular Atrophy

Total Page:16

File Type:pdf, Size:1020Kb

Spinal Muscular Atrophy FACT SHEET SPINAL MUSCULAR ATROPHY Spinal Muscular Atrophy (SMA) is a Motor Neuron Disease. It is caused by the mutation of the Survival of SYMPTOMS IN INFANTS • Muscle weakness. Motor Neuron (SMN) gene. It occurs due to the loss of • Muscle atrophy (wasting). motor neurons within the spinal cord and brain. It results • Poor muscle tone. in the progressive wasting away of muscles (atrophy) and • Areflexia (delayed reflexes). muscle weakness. SMA can affect people of all ages, races • Weak cry. or genders; however, the majority of cases occur in infancy • Difficulty sucking or swallowing. or childhood. There are four types of SMA. • Feeding difficulties. FORMS OF SMA • Weak cough. • Lack of developmental milestones (inability to lift head TYPE I (ACUTE INFANTILE) or sit up). • Also called Wernig-Hoffman Disease. • Limpness or a tendency to flop. • Most severe form of SMA. • Accumulations of secretions in the lungs or throat. • Usually diagnosed before six months of age. • Those affected cannot sit without support, lungs may SYMPTOMS IN ADULTS not fully develop, swallowing and breathing may be • Muscle weakness. difficult and there is weakness of the intercostal muscles • Muscle atrophy (wasting). (muscles between the ribs). • Weak tongue. • 95 per cent fatal by 18 • Stiffness. • Cramps. TYPE II (CHRONIC INFANTILE) • Fasciculation (twitching). • Usually diagnosed before the age of two, with the • Clumsiness. majority of cases diagnosed by 15 months. • Dyspnea (shortness of breath). • May be able to sit without assistance or even stand with support. DIAGNOSIS • Increased risk for complications from respiratory • A diagnosis can be made by an SMN gene test which infections. determines whether there are any traces of the SMN1 • Usually do not live past 30 years of age. gene. TYPE III (CHRONIC JUVENILE) • When the SMN gene test is not possible or shows no abnormality, an electromyography (EMG) or muscle • Also known as Kugelberg-Welander or Juvenile Spinal biopsy can be done. Muscular Atrophy. • Usually diagnosed before the age of three but can strike TREATMENT as late as adolescence. • Physical and occupational therapy. • Able to walk but experience noticeable weakness. • Ventilation is crucial, as many infants with severe forms • Most patients eventually need to use a wheelchair. of SMA succumb to respiratory disease due to weakness of • Usually survive well into adulthood with normal life breathing muscles. expectancy. • Assistive devices, such as ventilators and power wheel- chairs, help those living with SMA live longer and fuller TYPE IV (ADULT ONSET) • Much less common than the other forms. OTHER FACTS • Symptoms tend to surface after the age 35 but sometimes earlier. • Lifespan depends on the severity of SMA in the patient. • The bulbar muscles – used for swallowing and • Intellectual ability is unaffected. respiratory function – are rarely affected. • Sexual response and reproductive functions are also • Progression is slow and those affected have a normal life unaffected. expectancy. PROVINCIAL OFFICE ALS SOCIETY OF ALBERTA EDMONTON OFFICE 7874 10 STREET NE WWW.ALSAB.CA 5418 97 STREET NW CALGARY, AB T2E 8W1 1-888-309-1111 EDMONTON, AB T6E 5C1.
Recommended publications
  • Gluteal Muscle Contracture: Diagnosis and Management Options
    SICOT J 2017, 3,1 Ó The Authors, published by EDP Sciences, 2017 DOI: 10.1051/sicotj/2016036 Available online at: www.sicot-j.org REVIEW ARTICLE OPEN ACCESS Gluteal muscle contracture: diagnosis and management options Saroj Rai1, Chunqing Meng1,*, Xiaohong Wang1, Nabin Chaudhary2, Shengyang Jin1, Shuhua Yang1, and Hong Wang1 1 Department of Orthopedics, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, #1277 Jiefang Avenue, 430022 Wuhan, P.R. China 2 Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, #1095 Jiefang Avenue, 430030 Wuhan, P.R. China Received 14 April 2016, Accepted 29 October 2016, Published online 6 January 2017 Abstract – Gluteal muscle contracture (GMC), a debilitating disease, exists all over the globe but it is much more prevalent in China. Patients typically present with abduction and external rotation of the hip and are unable to bring both the knees together while squatting. Multiple etiologies have been postulated, the commonest being repeated intramuscular injection into the buttocks. The disease is diagnosed primarily by clinical features but radiological features are necessary for the exclusion of other pathological conditions. Non-operative treatment with physiotherapy can be tried before surgery is considered but it usually fails. Different surgical techniques have been described and claimed to have a better outcome of one over another but controversy still exists. Based on published literatures, the clinical outcome is exceptionally good in all established methods of surgery. However, endoscopic surgery is superior to conventional open surgery in terms of cosmetic outcome with fewer complications. Nevertheless, its use has been limited by lack of adequate knowledge, instrumentations, and some inherent limitations.
    [Show full text]
  • Cancer Cachexia Decreases Specific Force and Accelerates Fatigue in Limb Muscle
    Biochemical and Biophysical Research Communications 435 (2013) 488–492 Contents lists available at SciVerse ScienceDirect Biochemical and Biophysical Research Communications journal homepage: www.elsevier.com/locate/ybbrc Cancer cachexia decreases specific force and accelerates fatigue in limb muscle ⇑ B.M. Roberts a, G.S. Frye b, B. Ahn b, L.F. Ferreira b,1, A.R. Judge a,1, a 1225 Center Drive, HPNP Building Room 1142, Department of Physical Therapy, University of Florida, Gainesville, FL 32610, USA b 1864 Stadium Road, Department of Applied Physiology & Kinesiology, University of Florida, Gainesville, FL 32610, USA article info abstract Article history: Cancer cachexia is a complex metabolic syndrome that is characterized by the loss of skeletal muscle Received 30 April 2013 mass and weakness, which compromises physical function, reduces quality of life, and ultimately can Available online 11 May 2013 lead to mortality. Experimental models of cancer cachexia have recapitulated this skeletal muscle atro- phy and consequent decline in muscle force generating capacity. However, more recently, we provided Keywords: evidence that during severe cancer cachexia muscle weakness in the diaphragm muscle cannot be Muscle weakness entirely accounted for by the muscle atrophy. This indicates that muscle weakness is not just a conse- Muscle atrophy quence of muscle atrophy but that there is also significant contractile dysfunction. The current study C-26 aimed to determine whether contractile dysfunction is also present in limb muscles during severe Contractile dysfunction Colon-26 (C26) carcinoma cachexia by studying the glycolytic extensor digitorum longus (EDL) muscle and the oxidative soleus muscle, which has an activity pattern that more closely resembles the dia- phragm.
    [Show full text]
  • The Medical Management of Fibrodysplasia Ossificans Progressiva: Current Treatment Considerations
    THE MEDICAL MANAGEMENT OF FIBRODYSPLASIA OSSIFICANS PROGRESSIVA: CURRENT TREATMENT CONSIDERATIONS The International Clinical Consortium on Fibrodysplasia Ossificans Progressiva1 May 2011 From The Center for Research in FOP and Related Disorders, The University of Pennsylvania School of Medicine, Philadelphia, PA 19104 Corresponding Editor: Frederick S. Kaplan, M.D. Isaac and Rose Nassau Professor of Orthopaedic Molecular Medicine Director, Center for Research in FOP & Related Disorders The Perelman School of Medicine - The University of Pennsylvania Department of Orthopaedic Surgery 3737 Market Street – Sixth Floor Philadelphia, PA 19104, USA Tel: (office) 215-294-9145 Fax: 215-222-8854 Email: [email protected] Reprint Requests: [email protected] Associate Editors: Eileen M. Shore, Ph.D. Robert J. Pignolo, M.D., Ph.D. [Kaplan FS, Shore EM, Pignolo RJ (eds), name of individual consortium member, and The International Clinical Consortium on FOP. The medical management of fibrodysplasia ossificans progressiva: current treatment considerations. Clin Proc Intl Clin Consort FOP 4:1-100, 2011] 1See Section X (pages 84-100) for Complete Author Listing. ` 1 ABSTRACT…………………………………………………………………………………………… 5 I. THE CLINICAL AND BASIC SCIENCE BACKGROUND OF FOP……………..…………….. 6 A. Introduction………………………………………………………………..…..…..…………………. 6 B. Classic Clinical Features of FOP……………………………………………………..……………. 6 C. Other Skeletal Anomalies in FOP…………………………………………………………… 6 D. Radiographic Features of FOP……………………………………………………….…….... 7 E. Histopathology of FOP Lesions………………………………………………………………. 7 F. Laboratory Findings in FOP………………………………………………………………… 8 G. The Immune System & FOP…………………………………………………………………. 8 H. Misdiagnosis of FOP………………………………………………………………………………… 8 I. Epidemiologic, Genetic & Environmental Factors in FOP……………………..…………. 9 J. FOP & the BMP Signaling Pathway………………………………………………………… 9 K. The FOP Gene………………………………………………………………..………………. 9 L. Structural and Functional Consequences of the FOP Mutation…………………………… 10 M.
    [Show full text]
  • Spinal and Bulbar Muscular Atrophy
    Spinal and bulbar muscular atrophy Description Spinal and bulbar muscular atrophy, also known as Kennedy disease, is a disorder of specialized nerve cells that control muscle movement (motor neurons). These nerve cells originate in the spinal cord and the part of the brain that is connected to the spinal cord (the brainstem). Spinal and bulbar muscular atrophy mainly affects males and is characterized by muscle weakness and wasting (atrophy) that usually begins in adulthood and worsens slowly over time. Muscle wasting in the arms and legs results in cramping; leg muscle weakness can also lead to difficulty walking and a tendency to fall. Certain muscles in the face and throat (bulbar muscles) are also affected, which causes progressive problems with swallowing and speech. Additionally, muscle twitches (fasciculations) are common. Some males with the disorder experience unusual breast development ( gynecomastia) and may be unable to father a child (infertile). Frequency This condition affects fewer than 1 in 150,000 males and is very rare in females. Causes Spinal and bulbar muscular atrophy results from a particular type of mutation in the AR gene. This gene provides instructions for making a protein called an androgen receptor. This receptor attaches (binds) to a class of hormones called androgens, which are involved in male sexual development. Androgens and androgen receptors also have other important functions in both males and females, such as regulating hair growth and sex drive. The AR gene mutation that causes spinal and bulbar muscular atrophy is the abnormal expansion of a DNA segment called a CAG triplet repeat. Normally, this DNA segment is repeated up to about 36 times.
    [Show full text]
  • Skeletal Muscle Damage in COVID-19: a Call for Action
    medicina Review Skeletal Muscle Damage in COVID-19: A Call for Action Amira Mohammed Ali 1,2,* and Hiroshi Kunugi 3,4 1 Department of Psychiatric Nursing and Mental Health, Faculty of Nursing, Alexandria University, Alexandria 21527, Egypt 2 Department of Behavioral Medicine, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo 187-8553, Japan 3 Department of Psychiatry, School of Medicine, Teikyo University, Tokyo 173-8605, Japan; [email protected] 4 Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo 187-8551, Japan * Correspondence: [email protected]; Tel.: +81-042-346-1986 Abstract: Both laboratory investigations and body composition quantification measures (e.g., com- puted tomography, CT) portray muscle loss in symptomatic Coronavirus disease 2019 (COVID-19) patients. Muscle loss is associated with a poor prognosis of the disease. The exact mechanism of muscle damage in COVID-19 patients, as well as the long-term consequences of muscle injury in disease survivors, are unclear. The current review briefly summarizes the literature for mechanisms, assessment measures, and interventions relevant to skeletal muscle insult in COVID-19 patients. Muscle injury is likely to be attributed to the cytokine storm, disease severity, malnutrition, prolonged physical inactivity during intensive care unit (ICU) stays, mechanical ventilation, and myotoxic drugs (e.g., dexamethasone). It has been assessed by imaging and non-imaging techniques (e.g., CT and electromyography), physical performance tests (e.g., six-minute walk test), anthropometric measures (e.g., calf circumference), and biomarkers of muscle dystrophy (e.g., creatine kinase). Interventions Citation: Ali, A.M.; Kunugi, H.
    [Show full text]
  • Myalgia As the Revealing Symptom of Multicore Disease and Fibre Type Disproportion Myopathy C Sobreira*, W Marques Jr, a a Barreira
    1317 J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.74.9.1317 on 21 August 2003. Downloaded from SHORT REPORT Myalgia as the revealing symptom of multicore disease and fibre type disproportion myopathy C Sobreira*, W Marques Jr, A A Barreira ............................................................................................................................. J Neurol Neurosurg Psychiatry 2003;74:1317–1319 toms of CFTDM are more uniform. However, some patients Background: Multicore disease and congenital fibre type exhibit unusual phenotypes such as rigid spine syndrome,10 11 disproportion myopathy are diseases assigned to the significant dysmorphic features,12 or very mild symptoms.13 heterogeneous group of congenital myopathies. Although Cramps are uncommon complaints in patients with multi- hypotonia and muscle weakness appearing in early life core disease or CFTDM and exercise related muscle pain has are the commonest manifestations of these diseases, not been associated with multicore disease. Aimed at contrib- distinct phenotypes and late onset cases have been uting to better delineating the phenotypic expression of these described. myopathies, we present the clinical cases of patients suffering Objective: To report the occurrence of myalgia as the late onset, generalised muscle pain, whose muscle biopsies revealing symptom of multicore disease and fibre type dis- revealed the distinguishing features of either multicore proportion myopathy. disease or CFTDM. Methods: The clinical cases of three patients with fibre type disproportion myopathy and one with multicore CASE REPORTS disease are described. Skeletal muscle biopsies were Patient 1 processed for routine histological and histochemical A 24 year old man was referred to a neurologist owing to studies. exercise related myalgia involving both the upper and lower Results: The clinical picture was unusual in that the symp- limbs.
    [Show full text]
  • Steroid-Induced Myopathy and Its Significance to Respiratory Disease: a Known Disease Rediscovered
    Eur Respir J REVIEW 1992, 5, 997-1003 Steroid-induced myopathy and its significance to respiratory disease: a known disease rediscovered P.N.R. Dekhuijzen, M. Decramer Steroid-induced myopathy and its significance to respiratory disease: a known dis­ Respiratory Muscle Research Unit, ease rediscovered. P.N.R. Dekhuijzen, M. Decramer. Laboratory for Pneumology and Respi­ ABSTRACT: Skeletal muscle myopathy is a well-known side-effect of systemi­ ratory Division, University Hospital, cally administered corticosteroids. In recent years renewed attention is being Katholieke Universiteit Leuven, B-3000 Leuvcn, Belgium. paid to the involvement of the respiratory muscles and its consequent signifi­ cance in pulmonary patients. Two different clinical patterns of steroid-induced Correspondence: M. Decramer, Respira­ muscular changes are known. In acute myopathy and atrophy after short term tory Division, University Hospital, treatment with high doses of steroids, generalized muscle atrophy and Weligerveld I, 3212 Pellenberg, Bel­ rhabdomyolysis occur, including the respiratory muscles. Chronic steroid my­ gium opathy, occurring after prolonged treatment with moderate doses, is character­ ized by the gradual onset of proximal limb muscle weakness and may be Keywords: Atrophy accompanied by reduced respiratory muscle force. corticosteroids Animal studies demonstrated diaphragmatic myopathy and atrophy similar myopathy respiratory muscles to the alterations in peripheral skeletal muscles. Fluorinated steroids induced selective type lib (fast-twitch
    [Show full text]
  • Resistance Training with Vascular Occlusion in Inclusion Body Myositis: a Case Study
    Copyeditor: Jamaica Polintan Resistance Training with Vascular Occlusion in Inclusion Body Myositis: A Case Study BRUNO GUALANO1, MANOEL NEVES JR2, FERNANDA RODRIGUES LIMA2, ANA LU´ CIA DE SA´ PINTO2, GILBERTO LAURENTINO1, CLAUDIA BORGES2, LUCIANA BAPTISTA3, GUILHERME GIANNINI ARTIOLI1, MARCELO SALDANHA AOKI4, ANSELMO MORISCOT4, ANTONIO HERBERT LANCHA JR1, ELOI´SA BONFA´ 2, and CARLOS UGRINOWITSCH1 1School of Physical Education and Sport, University of Sa˜o Paulo, Sa˜o Paulo, BRAZIL; 2Division of Rheumatology, School of Medicine, University of Sa˜o Paulo, Sa˜o Paulo, BRAZIL; 3Hospital Nove de Julho, Sa˜o Paulo, BRAZIL; 4Institute of AQ1 Biomedical Sciences, University of Sa˜o Paulo, Sa˜o Paulo, BRAZIL; and 5School of Arts, Sciences, and Humanities, University of Sa˜o Paulo, Sa˜o Paulo, BRAZIL ABSTRACT GUALANO, B., M. NEVES JR, F. R. LIMA, A. L. PINTO, G. LAURENTINO, C. BORGES, L. BAPTISTA, G. G. ARTIOLI, M. S. AOKI, A. MORISCOT, A. H. LANCHA JR, E. BONFA´ , and C. UGRINOWITSCH. Resistance Training with Vascular Occlusion in Inclusion Body Myositis: A Case Study. Med. Sci. Sports Exerc., Vol. 42, No. 2, pp. 00–00, 2010. Inclusion body myositis (IBM) is a rare idiopathic inflammatory myopathy that produces remarkable muscle weakness. Resistance training with vascular occlusion has been shown to improve muscle strength and cross-sectional area in other muscle wasting conditions. Purpose: We evaluated the efficacy of a moderate-intensity resistance training program combined with vascular occlusion by examining functional capacity, muscle morphology, and changes in the expression of genes related to muscle protein synthesis and proteolysis in a patient with IBM. Methods: A 65-yr-old man with IBM resistant to all proposed treatments underwent resistance training with vascular occlusion for 12 wk.
    [Show full text]
  • If Treatment Fails, Think Inclusion Body Myositis
    38 Musculoskeletal Disorders FAMILY P RACTICE N EWS • November 1, 2007 If Treatment Fails, Think Inclusion Body Myositis BY DIANA MAHONEY polymyositis, said Dr. Oddis. “The results fore you get something you can hang your said Dr. Oddis. While no definitive treat- New England Bureau will be abnormal in both conditions, but hat on, but when you do, there is no ques- ment has been proven effective in achiev- MRIs from patients with inclusion body tion,” said Dr. Oddis. “The distinctive his- ing sustained remission and improvement B OSTON — Failure to respond to stan- myositis are more likely to show fatty in- tology that you’re looking for includes en- in whole body strength, some reports sug- dard immunosuppressant therapy may be filtration and atrophy and more widespread domysial inflammation, the presence of gest there may be a subgroup of patients the first sign that a patient’s apparent abnormalities, while in polymyositis, the rimmed vacuoles, and intracellular amy- who experience a partial, transient response polymyositis actually is inclusion body predominant abnormality seen on MRI is loid deposits or twisted tubulofilaments to anti-inflammatory, immunosuppressant myositis, according to Dr. Chester Oddis inflammation distributed along the fascia.” [containing hyperphosphorylated tau].” therapy. For this reason, he said, an initial of the University of Pittsburgh. The only definitive test for inclusion Management options for inclusion body 6-8 week trial of prednisolone and an im- The most common acquired muscle dis- body myositis is a muscle biopsy. Because myositis are often limited to supportive ef- munosuppressive drug such as methotrex- ease in people over 50 years of age, inclu- of the possibility of skip lesions, “it some- forts, such as myotomy to relieve dyspha- ate or azathioprine is a reasonable option sion body myositis (IBM) is a distinct type times takes two, three, or four biopsies be- gia caused by cricopharyngeal achalasia, for newly diagnosed patients.
    [Show full text]
  • Molecular Mechanisms of Cancer Cachexia‑Induced Muscle Atrophy (Review)
    MOLECULAR MEDICINE REPORTS 22: 4967-4980, 2020 Molecular mechanisms of cancer cachexia‑induced muscle atrophy (Review) WEI YANG1*, JIANHUI HUANG2*, HUI WU3, YUQING WANG3, ZHIYIN DU3, YUANBO LING3, WEIZHUO WANG3, QIAN WU1 and WENBIN GAO1 1Department of Oncology, The Third Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518000; 2Department of Oncology, Lishui Municipal Central Hospital, Lishui, Zhejiang 323000; 3Department of Clinical Medicine, Anhui University of Science and Technology, Huainan, Anhui 232001, P.R. China Received May 16, 2020; Accepted September 9, 2020 DOI: 10.3892/mmr.2020.11608 Abstract. Muscle atrophy is a severe clinical problem cachexia. Currently, the clinical morbidity and mortality rates involving the loss of muscle mass and strength that frequently of patients with cancer cachexia are high. Once a patient enters accompanies the development of numerous types of cancer, the cachexia phase, the consequences are difficult to reverse including pancreatic, lung and gastric cancers. Cancer cachexia and the treatment methods for cancer cachexia are very limited. is a multifactorial syndrome characterized by a continuous The present review aimed to summarize the recent discoveries decline in skeletal muscle mass that cannot be reversed by regarding the pathogenesis of cancer cachexia-induced muscle conventional nutritional therapy. The pathophysiological char- atrophy and provided novel ideas for the comprehensive acteristic of cancer cachexia is a negative protein and energy treatment to improve the prognosis of affected patients. balance caused by a combination of factors, including reduced food intake and metabolic abnormalities. Numerous necessary Contents cellular processes are disrupted by the presence of abnormal metabolites, which mediate several intracellular signaling 1.
    [Show full text]
  • Understanding Fibromyalgia and Its Resultant Disability
    IMAJ • VOL 13 • DeceMber 2011 REVIEWS Understanding Fibromyalgia and its Resultant Disability Ivy Grodman1, Dan Buskila MD2, Yoav Arnson MD1, Arie Altaman MD PhD1, Daniela Amital MD MHA3 and Howard Amital MD MHA1 1Department of Medicine B, Sheba Medical Center, Tel Hashomer, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel 2Division of Internal Medicine, Department of Medicine H, Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel 3Department of Psychiatry, Ness Ziona Mental Health Center, Ness Ziona, Israel a role in pain signaling, integration and modulation, suggest- KEY WORDS: fibromyalgia, central sensitization, disability, sleep ing that fibromyalgia patients have an enhanced sensitivity disturbance, pain to pain. IMAJ 2011; 13: 769–772 In addition, central sensitization is another mechanism to explain this increased perception of pain in fibromyalgia patients. Central sensitization includes spontaneous nerve activity, expanded receptive fields (resulting in a larger geographic distribution of pain), and augmented stimulus he introduction of the American College of Rheumatology responses within the spinal cord [10]. This pathway involves T fibromyalgia classification criteria 20 years ago heralded two triggering an N-Methyl-D-aspartate (NMDA) receptor, decades of professional acceptance and enhanced multidisci- which is thought to be involved in this abnormal temporal plinary research in the pathogenesis and therapy of fibromyalgia summation of pain stimuli [11]. [1]. Whereas the initial criteria included tenderness on pres- Muscular pathology has also been implicated in the patho- sure (tender points) in at least 11 of 18 defined anatomic sites physiology of tender points in the fibromyalgia syndrome.
    [Show full text]
  • Atrophy of Foot Muscles a Measure of Diabetic Neuropathy
    Pathophysiology/Complications ORIGINAL ARTICLE Atrophy of Foot Muscles A measure of diabetic neuropathy 1 HENNING ANDERSEN, MD, PHD athy that is easily detected in the feet and 1 MICHAELA D. GJERSTAD, MD is closely related to the severity of neurop- 1 JOHANNES JAKOBSEN, MD, PHD athy. In the present study, foot muscle volume was studied in a group of long- term diabetic patients with and without neuropathy and in a group of nondiabetic control subjects. OBJECTIVE — Diabetic neuropathy is a length-dependent process that leads to reduced muscle strength and atrophy of leg muscles in some patients. We hypothesized that intrinsic foot muscles are atrophied in diabetic neuropathy and that the degree of atrophy is a measure of RESEARCH DESIGN AND motor dysfunction closely related to the neuropathic process. METHODS — Twenty-three type 1 RESEARCH DESIGN AND METHODS — Consecutive cross-sectional magnetic reso- diabetic patients (16 men and 7 women) nance images of the nondominant foot were obtained for stereological determination of the total aged 46 years (median, range 27–62) volume of the intrinsic foot muscles (VFM) in 23 long-term diabetic patients with (n ϭ 15) and with a median diabetes duration of 29 without (n ϭ 8) chronic neuropathy and in 23 matched healthy nondiabetic control subjects. years (range 16–38) were included. The Based on clinical examination, nerve conduction studies, and quantitative sensory examination, mean body weight and body height were a neuropathy rank-sum score was calculated for each patient. 73 kg (range 53–92) and 176 cm (range 155–186), respectively. Diabetic patients 3 RESULTS — Total VFM was 86 Ϯ 52, 165 Ϯ 34, and 168 Ϯ 42 cm in neuropathic patients, without and with various degrees of neu- Ͻ nonneuropathic patients, and healthy control subjects, respectively (P 0.001).
    [Show full text]